These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10355825)

  • 1. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
    Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
    Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
    Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
    Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
    Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
    Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
    Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
    J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
    Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
    Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
    Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
    Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
    Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
    Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor interaction of short-course endostatin and ionizing radiation.
    Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
    Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
    Pei J; Zhang C; Gokhale PC; Rahman A; Dritschilo A; Ahmad I; Kasid UN
    Anticancer Drugs; 2004 Mar; 15(3):243-53. PubMed ID: 15014358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
    Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
    Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.